Q-omics provides the consensus-scored GCSAM profile across patient tissues and cancer cell-line models. GCSAM expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GCSAM is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, GCSAM RNA expression shows 16,982 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where GCSAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCSAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCSAM survival associations across molecular data types. GCSAM RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCSAM RNA expression–survival associations across cancer types. High GCSAM expression shows unfavorable associations in UVM, KIRP and LGG, but favorable associations in HNSC, LUAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GCSAM RNA expression.
This table summarizes GCSAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GCSAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCSAM shows lower tumor expression in THCA, COAD, LUAD, KICH and UCEC and higher tumor expression in HNSC. The THCA box plot shows higher GCSAM RNA expression in normal versus tumor tissue (log2 FC = −1.678, t-test p < 0.001).
This table shows molecular features associated with GCSAM in patient tissues and cancer cell lines. In patient samples, GCSAM shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GCSAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
